EATRIS-Plus

Project information

• Full title: EATRIS-Plus – Flagship in personalised medicine / European Advanced Translational Research Infrastructure in Medicine
• Duration: 48 months, (1 January 2020  - 31 December 2023)
• Status: ongoing, coordinated by EATRIS ERIC
• Funding programme: Horizon 2020 – the European Union Framework Programme for Research and Innovation (Grant agreement ID: 871096)

What will the project do?

• EATRIS-Plus will aim to support the long-term sustainability of EATRIS by delivering innovative scientific tools to the research community, strengthening the EATRIS financial model, and reinforcing EATRIS’ leadership in the European Research Area, particularly in the field of Personalised Medicine research and development.

• EATRIS is a non-profit European Research Infrastructure Consortium (ERIC) providing research services, combined expertise, and high-end technologies in translational medicine.

What are the expected outcomes?

• To drive patient empowerment through active involvement in EATRIS operations.
• To increase the number of EATRIS innovation hubs with medicines developers.
• To consolidate the capacities of EATRIS in the field of personalised medicine (particularly genomics, transcriptomics, proteomics, metabolomics) to support academics, researchers, and medicine developers in their work.
• To expand strategic partnerships with research infrastructures and other relevant stakeholders.

What is EPFs role?

• EPF is leading on  the work on Stakeholder Engagement.
• We will deliver a Patient Advisory Committee to drive patient empowerment at the heart of EATRIS operations, and develop a patient involvement toolkit for translational researchers.
• We will also leverage our network to support in the international collaboration aspects of the work, including promoting more patient-driven research, launching a joint advocacy programme, and position papers with patient perspectives which are central to the work of the project.

Why does this matter for patients?

• EATRIS-Plus will work towards improving the understanding, data-sharing, and clinical needs of how gene, protein, mRNA and metabolite analysis will directly impact Personalised Medicine Solutions. Personalised medicine research aims to identify interventions that can be targeted to individual patients based on their predicted response. This has enormous value for patients, as it can reduce trial-and-error treatments, enable better choices for determining which medications would be most effective, and it can help to manage rising healthcare costs

Consortium

• The consortium is composed of 19 partners including all current national nodes of the research infrastructure, academic representatives of new prospective member countries as well as umbrella organisations representing the patients’ voice and biotech companies.
• • EATRIS-ERIC, The Netherlands
  • Palacký University Olomouc, Czechia
  • Madrid Health Service, Spain
  • University of Helsinki, Finland
  • Luxembourg Institute of Health/Integrated Biobank Of Luxembourg, Luxembourg
  • Radboud University Medical Centre, The Netherlands
  • University of Ljubljana, Slovenia
  • Trinity College Dublin, Ireland
  • Riga Stradins University, Latvia
  • Uppsala University, Sweden
  • Technical University of Munich, Germany
  • European Patients’ Forum, Luxembourg
  • Vall D’Hebron Research Institute, Spain
  • CEA-NeurATRIS, France
  • Italian National Institute of Health, Italy
  • University Of Oslo, Norway
  • BIOCAT, Spain
  • INFARMED, Portugal
  • Sofia University, Bulgaria